{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T19:43:00Z","timestamp":1765741380177,"version":"3.48.0"},"reference-count":31,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"FCT\/MCTES","award":["UIDB\/05608\/2020"],"award-info":[{"award-number":["UIDB\/05608\/2020"]}]},{"name":"FCT\/MCTES","award":["UIDP\/05608\/2020"],"award-info":[{"award-number":["UIDP\/05608\/2020"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,1,22]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Sickle cell disease (SCD), an inherited haemoglobinopathy, has important impact on morbidity and mortality, especially in paediatrics. Previous systematic reviews are limited to adult patients or focused only on few therapies. We aim to synthesise the evidence on efficacy and safety of pharmacological interventions for managing SCD in children and adolescents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This systematic review protocol is available at Open Science Framework (doi:10.17605\/OSF.IO\/CWAE9). We will follow international recommendations on conduction and report of systematic reviews and meta-analyses. Searches will be conducted in PubMed, Scopus and Web of Science (no language nor time restrictions) (first pilot searches performed in May 2022). We will include randomised controlled trials comparing the effects of disease-modifying agents in patients with SCD under 18 years old. Outcomes of interest will include: vaso-occlusive crisis, haemoglobin levels, chest syndrome, stroke, overall survival and adverse events. We will provide a narrative synthesis of the findings, and whenever possible, results will be pooled by means of pairwise or Bayesian network meta-analyses with surface under the cumulative ranking curve analyses. Different statistical methods and models will be tested. Dichotomous outcomes will be reported as OR, risk ratio or HR, while continuous data will be reported as standard mean differences, both with 95% CI\/credibility interval. The methodological quality of the trials will be evaluated using the Risk of Bias 2.0 tool, and the certainty of the evidence will be assessed with the Grading of Recommendations Assessment, Development and Evaluation approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study refers to a systematic review, so no ethics approval is necessary. We intent to publish our findings in international, peer-reviewed journal. Data will also be presented to peers in scientific events. Additionally, the results obtained in this study may contribute towards the update of therapeutic guidelines and for the development of health policies for SCD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42022328471.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-064872","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T11:12:58Z","timestamp":1675681978000},"page":"e064872","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of pharmacological interventions for managing sickle cell disease in children and adolescents: protocol for a systematic review with network meta-analysis"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-8608","authenticated-orcid":false,"given":"Fernanda S","family":"Tonin","sequence":"first","affiliation":[{"name":"Health & Technology Research Center (H&TRC), Escola Superior de Tecnologia da Sa\u00fade de Lisboa, Instituto Polit\u00e9cnico de Lisboa, Lisbon, Portugal"},{"name":"Pharmaceutical Sciences Postgraduate Programme, Federal University of Paran\u00e1, Curitiba, Brazil"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2334-782X","authenticated-orcid":false,"given":"Catarina","family":"Ginete","sequence":"additional","affiliation":[{"name":"Health & Technology Research Center (H&TRC), Escola Superior de Tecnologia da Sa\u00fade de Lisboa, Instituto Polit\u00e9cnico de Lisboa, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8529-9595","authenticated-orcid":false,"given":"Fernando","family":"Fernandez-Llimos","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4865-564X","authenticated-orcid":false,"given":"Joana","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Health & Technology Research Center (H&TRC), Escola Superior de Tecnologia da Sa\u00fade de Lisboa, Instituto Polit\u00e9cnico de Lisboa, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0586-9154","authenticated-orcid":false,"given":"Mariana","family":"Delgadinho","sequence":"additional","affiliation":[{"name":"Health & Technology Research Center (H&TRC), Escola Superior de Tecnologia da Sa\u00fade de Lisboa, Instituto Polit\u00e9cnico de Lisboa, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6394-658X","authenticated-orcid":false,"given":"Miguel","family":"Brito","sequence":"additional","affiliation":[{"name":"Health & Technology Research Center (H&TRC), Escola Superior de Tecnologia da Sa\u00fade de Lisboa, Instituto Polit\u00e9cnico de Lisboa, Lisbon, Portugal"}]}],"member":"239","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"2025121411405088000_13.2.e064872.1","doi-asserted-by":"crossref","unstructured":"Marks LJ , Munube D , Kasirye P , et al . Stroke prevalence in children with sickle cell disease in sub-saharan africa: a systematic review and meta-analysis. Glob Pediatr Health 2018;5. doi:10.1177\/2333794X18774970","DOI":"10.1177\/2333794X18774970"},{"key":"2025121411405088000_13.2.e064872.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61229-X"},{"key":"2025121411405088000_13.2.e064872.3","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1182\/bloodadvances.2019001142","article-title":"American Society of hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults","volume":"4","author":"DeBaun","year":"2020","journal-title":"Blood Adv"},{"key":"2025121411405088000_13.2.e064872.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-599852"},{"key":"2025121411405088000_13.2.e064872.5","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.annemergmed.2020.08.009","article-title":"Trends in sickle cell disease-related mortality in the united states, 1979 to 2017","volume":"76","author":"Payne","year":"2020","journal-title":"Ann Emerg Med"},{"key":"2025121411405088000_13.2.e064872.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2011.09.013"},{"key":"2025121411405088000_13.2.e064872.7","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01237-z","article-title":"Advances in the diagnosis and treatment of sickle cell disease","volume":"15","author":"Brandow","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2025121411405088000_13.2.e064872.8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3233\/CH-189002","article-title":"Sickle cell disease: classification of clinical complications and approaches to preventive and therapeutic management","volume":"68","author":"Ballas","year":"2018","journal-title":"Clin Hemorheol Microcirc"},{"key":"2025121411405088000_13.2.e064872.9","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-021-01413-8","article-title":"CoreSCD: multi-stakeholder consensus on core outcomes for sickle cell disease clinical trials","volume":"21","author":"Tambor","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"2025121411405088000_13.2.e064872.10","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.00435","article-title":"Recent advances in the treatment of sickle cell disease","volume":"11","author":"Salinas Cisneros","year":"2020","journal-title":"Front Physiol"},{"key":"2025121411405088000_13.2.e064872.11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.207357"},{"key":"2025121411405088000_13.2.e064872.12","doi-asserted-by":"crossref","first-page":"100925","DOI":"10.1016\/j.blre.2021.100925","article-title":"L-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: hype or hope?","volume":"53","author":"Leibovitch","year":"2022","journal-title":"Blood Rev"},{"key":"2025121411405088000_13.2.e064872.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034147","article-title":"Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis","volume":"10","author":"Thom","year":"2020","journal-title":"BMJ Open"},{"key":"2025121411405088000_13.2.e064872.14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1367493518814922","article-title":"Hydroxyurea can be used in children with sickle cell disease and cerebral vasculopathy for the prevention of chronic complications? A meta-analysis","volume":"24","author":"N\u00fa\u00f1ez","year":"2020","journal-title":"J Child Health Care"},{"key":"2025121411405088000_13.2.e064872.15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jtct.2020.10.007","article-title":"Systematic review\/meta-analysis on efficacy of allogeneic hematopoietic cell transplantation in sickle cell disease: an international effort on behalf of the pediatric diseases working party of european society for blood and marrow transplantation and the sickle cell transplantation international consortium","volume":"27","author":"Iqbal","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2025121411405088000_13.2.e064872.16","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-018-3556-0","article-title":"Safety and effectiveness of antimalarial therapy in sickle cell disease: a systematic review and network meta-analysis","volume":"18","author":"Frimpong","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2025121411405088000_13.2.e064872.17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ajh.25626","article-title":"Perioperative care of children with sickle cell disease: a systematic review and clinical recommendations","volume":"95","author":"Schyrr","year":"2020","journal-title":"Am J Hematol"},{"key":"2025121411405088000_13.2.e064872.18","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2025121411405088000_13.2.e064872.19","doi-asserted-by":"crossref","unstructured":"Higgins JPT , Thomas J , Chandler J , et al . Cochrane handbook for systematic reviews of interventions. Cochrane, 23 September 2019. doi:10.1002\/9781119536604","DOI":"10.1002\/9781119536604"},{"key":"2025121411405088000_13.2.e064872.20","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"2025121411405088000_13.2.e064872.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025121411405088000_13.2.e064872.22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"key":"2025121411405088000_13.2.e064872.23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I2 is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Res Synth Methods"},{"key":"2025121411405088000_13.2.e064872.24","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-2-3","article-title":"Meta-Analysis, Simpson\u2019s paradox, and the number needed to treat","volume":"2","author":"Altman","year":"2002","journal-title":"BMC Med Res Methodol"},{"key":"2025121411405088000_13.2.e064872.25","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.sapharm.2021.06.002","article-title":"Methodological standards for conducting and reporting meta-analyses: ensuring the replicability of meta-analyses of pharmacist-led medication review","volume":"18","author":"Bonetti","year":"2022","journal-title":"Res Social Adm Pharm"},{"key":"2025121411405088000_13.2.e064872.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.01.011"},{"key":"2025121411405088000_13.2.e064872.27","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/ije\/dyy197","article-title":"Methodological quality assessment of network meta-analysis of drug interventions: implications from a systematic review","volume":"48","author":"Tonin","year":"2019","journal-title":"Int J Epidemiol"},{"key":"2025121411405088000_13.2.e064872.28","first-page":"133","article-title":"The attractiveness of network meta-analysis: a comprehensive systematic and narrative review","volume":"7","author":"Greco","year":"2015","journal-title":"Heart Lung Vessel"},{"key":"2025121411405088000_13.2.e064872.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.04.002"},{"key":"2025121411405088000_13.2.e064872.30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212650","article-title":"Description of network meta-analysis geometry: a metrics design study","volume":"14","author":"Tonin","year":"2019","journal-title":"PLoS One"},{"key":"2025121411405088000_13.2.e064872.31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7454.1490"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-064872","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T19:41:01Z","timestamp":1765741261000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-064872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,6]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/bmjopen-2022-064872"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-064872","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}